SCHEMBL31662083

SCHEMBL31662083

Cc1cc2[nH]ncc2c(-c2nc(OC(C)C)c3c(NCCO)nc(OC[C@@]45CCCN4C[C@H](F)C5)nc3c2F)c1C

nearest known ligand 0.55

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KRAS P01116 20/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31662251 0.94 KRAS (0.54) KRAS
SCHEMBL31662102 0.93 KRAS (0.52) KRAS
SCHEMBL31662009 0.88 KRAS (0.55) KRAS
SCHEMBL31662037 0.80 KRAS (0.51) KRAS
SCHEMBL31662286 0.79 KRAS (0.42) KRAS
SCHEMBL31527456 0.78 KRAS (0.57) KRAS
SCHEMBL31662318 0.78 KRAS (0.57) KRAS
SCHEMBL31527205 0.77 KRAS (0.56) KRAS
SCHEMBL31662313 0.77 KRAS (0.61) KRAS
SCHEMBL30706963 0.76 KRAS (0.66) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 WO disclosed